×
I’m Both Terrified and Impatient for Pennywise to Show Up on ‘Welcome to Derry’

I’m Both Terrified and Impatient for Pennywise to Show Up on ‘Welcome to Derry’

There have been two episodes of It: Welcome to Derry, and Pennywise is taking his sweet time to make his entrance as dramatic and traumatic as possible.

Since the marketing has been all in on making sure you know Bill Skarsgård is back, we’ve been excited to see how film franchise director Andy Muschietti is planning to have his first small-screen appearance as Pennywise the Dancing Clown come into play.

In io9’s recent chat with the minds behind the show, which expands the Stephen King It universe, Jason Fuchs (writer, producer, and co-showrunner) shared that they “wanted to understand why a shape-shifter who has a virtually infinite number of forms it could take continues to take the form of Pennywise the Dancing Clown.” He also said that fans can expect to get “really satisfying answers to some of those things in the context of the show. But the answers themselves suggest fresh mysteries and new questions.” Since they were given free rein by King himself to do whatever they want, we’re anxious to see how much new input they’re putting into the horror legend’s scariest creation.

So far we have so many questions! The first couple episodes truly play with the expectations of how It is perceived, playing tricks on the audience’s minds as well as its young characters. It begins with that gnarly birthing scene where the fleshy demon bat baby comes out to feast on the children of Derry, starting with Matty Clements. This grotesque incarnation makes us wonder if it’s just It awakening from its cyclical slumber in the most dramatic way possible or if it’s reborn every time and quickly evolves into a bigger form the more kids it claims.

By the end of the episode, it goes from the size of an eagle to a bigger creature when it takes out half the kids that were introduced. This isn’t Stranger Things; we at least get the sense that no one is safe. Everyone in Derry who has a fair share of darkness and trauma is game for It. And that point is made very clearly as we meet new characters.

© HBO Max

In episode two, the surviving girls, Lilly (Clara Stack) and Ronnie (Amanda Christine), are preyed on through It taking the forms of their dead parents. Not as a clown, but instead giving Ronnie the major retraumatization of being birthed by a demonic version of her mom, who passed away when she was born. Likewise, Lilly faces her father in the form of It, taking pieces of him in pickle jars to scare her. But again, it raises a lot of ideas of how It decides to masquerade. Was It really the demon mom or pickled, dead daddy? Or were these just projections it could manipulate? They both disappear instantly; we’re leaning toward more projections than a corporeal outfit that It chooses to take.

Why the entity chooses to don its iconic clown garb has yet to be explored despite marketing bombarding us with Pennywise’s signature look. If we think back on It: Chapter Two, you might recall that there’s a scene where Beverly encounters Pennywise getting ready and looking most definitely like a man putting on clown makeup in a twisted “Get Ready With Me’ moment; we even see It use its fingernails to tear the red lines onto its face.

Welcome To Derry Pennywise Makeup Hbo Max
© Warner Bros. Pictures

The trailers tease that the circus or carnival origin story is coming, with glimpses of Skarsgård in his creepy man form without makeup, as we’ve seen in the movies. Hopefully in this Sunday’s episode, we’ll get more lore about Its origin; the entity has been encountered by the Indigenous people around Derry in the past, who have had more knowledge of its presence as an ancient being or alien. Perhaps It body-snatched a carnie after its previous host was destroyed. Because otherwise, why does It go through the effort to put on the face? It can’t be just for funzies, right?  If he can just morph into anything, why go through the effort to put on his dancing clown face?  It feels like there is an element of having a main form as a corporeal host to unleash its horrors. We are itching to find out more and to see Skarsgård return.

It: Welcome to Derry streams Sundays on HBO Max.

Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.

Source link
#Terrified #Impatient #Pennywise #Show #Derry

officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna">Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna">Luna Introduces Luna Band With Real-Time Health Tracking Features

Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna
suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know

Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders.

Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

Post Comment